시장보고서
상품코드
1172475

세계의 리포솜 개발 및 리포솜 제조 서비스 시장 : 제품 제제 유형별, 사업 규모별, 최종 사용자 업계별, 주요 지역별 : 업계 동향과 예측(2022-2035년)

Liposome Development and Liposome Manufacturing Services Market, 2022-2035: Distribution by Type of Product Formulation, Scale of Operation, End User Industry, Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035

발행일: | 리서치사: Roots Analysis | 페이지 정보: 영문 226 Pages | 배송안내 : 1-2일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 리포솜 개발 및 리포솜 제조 서비스(Liposome Development and Liposome Manufacturing Services) 시장을 조사했으며 시장 개요와 더불어 제품 제형 유형별, 비즈니스 규모별, 최종 사용자 업계별, 주요 지역별 동향 및 시장에 진입하는 기업 프로필 등을 제공합니다.

목차

제1장 서문

제2장 사업 요약

제3장 소개

  • 장 개요
  • 리포솜 소개
  • 리포솜 형성
  • 리포솜 분류
  • 드래그 딜리버리 시스템으로서의 리포솜
  • 리포솜 조제 방법
  • 준비 후 처리
  • 리포솜 분석과 특성화
  • 리포솜 제약 및 산업에 응용
  • 리포솜 개발과 제조에서의 과제
  • 리포솜 개발·제조 아웃소싱 필요성
  • 장래 전망

제4장 시장 시장 상황 : 리포솜 개발 및 리포솜 제조 서비스 제공업체

  • 장 개요
  • 리포솜 개발 및 리포솜 제조 서비스 제공자 상황

제5장 기업 프로필

  • 장 개요
  • 북미를 거점으로 하는 주요 참가 기업
  • 유럽을 거점으로 하는 주요 참가 기업
  • 아시아태평양을 거점으로 하는 주요 진입 기업

제6장 임상시험 분석

  • 장 개요
  • 범위와 조사 방법
  • 리포솜: 임상 시험 분석

제7장 출판물 분석

제8장 특허 분석

제9장 세계의 이벤트 분석

제10장 아웃소싱: GO/NO-GO 프레임워크

제11장 시장 예측과 기회 분석

  • 장 개요
  • 주요 가정과 조사 방법
  • 세계의 리포솜 개발 및 제조 서비스 시장, 2022-2035년

제12장 매듭 말

제13장 사업 인사이트

제14장 부록 1: 테이블 형식 데이터

제15장 부록 2: 회사 및 조직 목록

NJH 22.12.27

INTRODUCTION

Around 90% of the drug candidates in the current development pipeline and close to 40% of marketed pharmacological products, have concerns related to solubility and / or permeability. Therefore, players engaged in the pharmaceutical industry are actively trying to identify ways to improve / augment physiochemical properties and drug-like behavior of pharmacological products. Amidst other alternatives, liposomes (which improve permeability across biological membranes), have garnered the attention of drug developers. Liposomes are small artificial vesicles that have the ability to encapsulate, deliver and release low-soluble drugs and small molecules to a specific site in the body. Over time, various research studies have demonstrated the potential of liposomes in disease diagnosis and drug delivery applications, owing to their ability to self-assemble, carry large drug payloads, act as biomarkers for various diseases and transport important functional elements. Given the various benefits, liposomes have gained significant interest in the biopharmaceutical industry, which is anticipated to increase their demand in future. However, the development and manufacturing of liposomes is associated with several challenges, including complex manufacturing processes, huge capital investments, inadequate clinical grade production and GMP compliant industrial scale-up, lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. Therefore, considering the aforementioned challenges, a number of pharmaceutical companies have demonstrated the preference to outsource their respective liposome development and manufacturing operations to specialized service providers.

Q1. What is the current market landscape of the liposome development and manufacturing services market?

The liposome development and manufacturing services market is amongst one of the most dynamic sectors of the biopharmaceutical industry. Presently, more than 70 companies have the required capabilities to offer liposome development and manufacturing services across different geographical locations. These service providers employ a variety of analysis and characterization methods for liposome development.

Q2. How has outsourcing evolved in the liposome development and manufacturing domain?

The manufacturing of highly potent liposome-based therapeutics requires an adequate working environment (to prevent cross contamination within multi-product assets), stringent manufacturing protocols (to comply with the established regulatory standards) and a trained workforce (to satisfactorily handle highly potent materials). In addition, it requires an expensive infrastructure, which is often complex to engineer, install and maintain. As a result, various companies rely on third party service providers to leverage their technologies for manufacturing these therapeutics and achieve greater operational flexibility. The inherent expertise of CMOs is believed to be capable of enabling reduction in the time-to-market a product and offer significant cost-benefits.

Q3. What are the recent developments and expected trends in the liposome development and manufacturing domain?

In recent years, several events have been organized by various researchers / industry stakeholders in order to consolidate their presence in this field and enhance their existing capabilities to meet the growing demand for these novel drug delivery systems. It is worth mentioning that majority of the events were focused on discussing the analytical method development, manufacturing and process development steps for liposomes.

Q4. What are the key challenges faced by liposome development and manufacturing service providers?

The primary challenge faced by these service providers is associated with the poor stability of liposomes under shelf and in vivo conditions. This is mainly caused by the possibility of lipid oxidation and hydrolysis, leakage and loss of hydrophilic cargos, along with fission and fusion of particles. Currently, some of these issues can be overcome by experimenting with formulation adjuvants, including antioxidants, or post-preparation processing, such as freeze-thawing and freeze-drying. Further, since the manufacturing of liposomes on large-scale is a multi-step and multi-test process, therefore, innovation in this domain is essential in order to overcome the challenges.

Q5. What are the key value drivers in the liposome development and manufacturing services market?

The increasing demand for novel drug delivery systems for effective delivery has led to a rise in the number of liposome-based therapeutics in the overall biopharmaceutical development pipeline. In order to cater to the growing demand for such therapeutics, there is a requirement for safe manufacturing technologies. Although some biopharmaceutical companies have made considerable investments to establish in-house capabilities, the capital-intensive nature and specialized containment requirements make the role of contract manufacturers crucial, specifically for small and mid-sized developers.

Q6. What is the current market scenario and likely growth associated with the liposome development and manufacturing services domain?

The liposome development and manufacturing services market is anticipated to grow at a steady pace in the coming years. Among various other types of product formulations, the therapeutic formulations of liposomes are anticipated to capture the maximum share. Further, in terms of end-users, the pharmaceutical and biotechnology industry stakeholders are most likely to outsource their liposome development and manufacturing operations to service providers as these companies primarily employ liposomes at commercial scale for delivering drugs to the target sites. Specifically, in terms of geography, the liposome development and manufacturing services market in Latin America is likely to grow at a relatively faster pace in the long term.

SCOPE OF THE REPORT

The 'Liposome Development and Manufacturing Services Market, 2022-2035: Distribution by Type of Product Formulation (Therapeutic and Nutraceutical), Scale of Operation (Discovery / Research, Preclinical, Clinical and Commercial), End User Industry (Pharmaceutical and Biotechnology, Cosmetics, Food, Agricultural, Academic and Other Industries), Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America): Industry Trends and Global Forecasts, 2022-2035' report features an extensive study of the current market landscape and future potential of the liposome development and manufacturing services market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing liposome development and manufacturing services. Amongst other elements, the report includes:

  • A general overview of liposomes, along with information on the formation and classification of liposomes. Further, the chapter also lays emphasis on liposome as a drug delivery system, liposomal drug delivery platforms and therapeutic applications of liposomes in drug delivery. Additionally, it highlights the methods for liposome preparation, post-preparation treatments, liposome analysis and characterization methods, pharmaceutical and industrial applications of liposomes. Further, it also features a discussion on the challenges in this domain and need for outsourcing of liposome development and manufacturing operations.
  • A detailed assessment of the overall market landscape of liposome development and manufacturing service providers, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), region of headquarters, types of method(s) for liposome preparation, type of service(s) offered (formulation development, analytical method development, contract manufacturing, process development, quality control, GMP manufacturing, characterization, fill / finish, clinical and regulatory support, feasibility studies, screening and liposome conjugation), liposome bioconjugation target(s) (protein, small molecule, lipid, peptide, nucleic acid, vaccine antigen, vitamin, oligonucleotide, carbohydrate and mineral), scalability (small, mid and large), liposome analysis and characterization method(s) (stability analysis, encapsulation efficiency determination, size analysis, drug release kinetics, lipid content analysis, lamellarity analysis and permeability analysis), application(s) of liposomes (drug delivery, cancer therapy and gene therapy), scale of operation (discovery / research, preclinical, clinical and commercial) and end user industry (pharmaceutical and biotechnology, food, academic, cosmetics, agricultural and other industries).
  • Elaborate profiles of the prominent (shortlisted based on a proprietary criterion) players offering liposome development and manufacturing services, across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, its financial information (if available), information on its service portfolio, recent developments and an informed future outlook.
  • A detailed analysis of completed, ongoing and planned clinical studies related to liposomes, highlighting prevalent trends across different parameters, such as trial registration year, trial status, trial registration year and patients enrolled, trial phase, type of sponsor / collaborator, study design, leading players (in terms of number of trials conducted), disease indication(s), popular therapeutic areas, type of treatment, emerging focus areas and regional distribution of trials (in terms of number of trials conducted and trial status).
  • A detailed review of more than 6,000 peer-reviewed, scientific articles related to research on liposomes, based on several relevant parameters, such as year of publication, application area(s), and emerging focus areas. The chapter also highlights the top journals (in terms of number of publications and impact factor).
  • An insightful analysis of the patents filed / granted for liposomes, since 2017, taking into consideration various relevant parameters, such as type of patent, patent publication year, granted patents and patent applications, geography, CPC symbols, emerging focus areas, type of organization, leading players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis, highlighting the leading patents (in terms of number of citations).
  • An in-depth analysis of recent events (webinars / conferences / seminars / workshops / symposiums / summits) that were organized for stakeholders in this domain, based on several relevant parameters, such as year of event, event platform, type of event, geography, evolutionary trends in event agenda, most active event organizers, active industry and non-industry players (in terms of number of events that each company participated in), seniority level of event speakers, affiliated department of event speakers, most active speakers (in terms of number of events) and a geographical mapping of upcoming events.
  • An insightful outsourcing: go / no-go framework analysis, highlighting the various factors that need to be taken into consideration by liposome developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, large and very large), while taking the aforementioned decision.

One of the key objectives of the report was to evaluate the current opportunity and the future growth potential associated with the liposome development and manufacturing services market, over the coming years. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of product formulation (therapeutic and nutraceutical), scale of operation (discovery / research, preclinical, clinical and commercial), end user industry (pharmaceutical and biotechnology, cosmetics, food, agricultural, academic and other industries), key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. The information is primarily useful for us to draw out our opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent views on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED:

  • Who are the key players offering liposome development and manufacturing services?
  • What is the evolving trend of publications focused on liposomes?
  • How many patents, related to liposomes, have been filed / granted in the past few years?
  • Which companies are actively involved in conducting clinical trials for liposomes?
  • What are the key agenda items being discussed in various global events / conferences related to liposomes?
  • How is the current and future market opportunity related to liposome development and manufacturing services, likely to be distributed across key market segments?

CHAPTER OUTLINES

  • Chapter 2: is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of liposome development and manufacturing services market and its likely evolution in the short-mid to long term.
  • Chapter 3: provides a brief overview of liposomes, featuring information on the formation and classification of liposomes. Further, the chapter also lays emphasis on liposome as a drug delivery system, liposomal drug delivery platforms and therapeutic applications of liposomes in drug delivery. Additionally, it highlights the methods for liposome preparation, post-preparation treatments, liposome analysis and characterization methods, pharmaceutical and industrial applications of liposomes. Further, it also features a discussion on the challenges in this domain and need for outsourcing of liposome development and manufacturing operations.
  • Chapter 4: presents an overview of the current market landscape of liposome development and manufacturing service providers, featuring a detailed analysis based on several parameters, such as year of establishment, company size (in terms of number of employees), region of headquarters, types of method(s) for liposome preparation, type of service(s) offered (formulation development, analytical method development, contract manufacturing, process development, quality control, GMP manufacturing, characterization, fill / finish, clinical and regulatory support, feasibility studies, screening and liposome conjugation), liposome bioconjugation target(s) (protein, small molecule, lipid, peptide, nucleic acid, vaccine antigen, vitamin, oligonucleotide, carbohydrate and mineral), scalability (small, mid and large), liposome analysis and characterization method(s) (stability analysis, encapsulation efficiency determination, size analysis, drug release kinetics, lipid content analysis, lamellarity analysis and permeability analysis), application(s) of liposomes (drug delivery, cancer therapy and gene therapy), scale of operation (discovery / research, preclinical, clinical and commercial) and end user industry (pharmaceutical and biotechnology, food, academic, cosmetics, agricultural and other industries).
  • Chapter 5: includes profiles of the key players (shortlisted based on a proprietary criterion) offering liposome development and manufacturing services, across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, its financial information (if available), details on its service portfolio, recent developments and an informed future outlook.
  • Chapter 6: provides information on more than 800 completed, ongoing and planned clinical studies of liposomes, based on different parameters, such as trial registration year, trial status, trial registration year and patients enrolled, trial phase, type of sponsor / collaborator, and study design. In addition, the chapter highlights leading industry and non-industry players (in terms of number of trials conducted), key indication(s), popular therapeutics area(s), type of treatment, emerging focus areas and regional distribution of trials (in terms of number of trials conducted and trial status).
  • Chapter 7: features a detailed review of more than 6,000 peer-reviewed, scientific articles related to research on liposomes, based on parameters, such as year of publication, application area(s), emerging focus areas, top authors, key journals (in terms of number of publications and impact factor).
  • Chapter 8: features an in-depth analysis of the patents that have been filed / granted for liposomes, since 2017. The analysis also highlights the key trends associated with the patents, such as the type of patent (granted patent, patent application and others), patent publication year, granted patents and patent applications, geography, CPC symbols, emerging focus areas, type of organization, leading players (in terms of number of patents granted / filed). In addition, it includes detailed patent benchmarking and valuation analysis based on patent characteristics.
  • Chapter 9: provides an analysis of recent events (webinars / conferences / seminars / workshops / symposiums / summits) related to liposomes that were organized / planned. It features an analysis based on year of event, event platform, type of event, geography, evolutionary trends in event agenda, most active event organizers, active industry and non-industry players (in terms of number of events that each company participated in), seniority level of event speakers, affiliated department of event speakers, most active speakers (in terms of number of events) and a geographical mapping of upcoming events.
  • Chapter 10: presents an insightful outsourcing: go / no-go framework analysis that highlights the various factors that need to be taken into consideration by liposome developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, large and very large), while taking the aforementioned decision.
  • Chapter 11: features a detailed market forecast of the likely growth of liposome development and manufacturing services market, till the year 2035. It also includes insights on the likely distribution of the current and forecasted opportunity across the type of product formulation (therapeutic and nutraceutical), scale of operation (discovery / research, preclinical, clinical and commercial), end user industry (pharmaceutical and biotechnology, cosmetics, food, agricultural, academic and other industries), key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America).
  • Chapter 12: is a summary of the overall report, presenting insights on the contemporary market trends and the likely evolution of the liposome development and manufacturing services market.
  • Chapter 13: provides the transcripts of the interviews conducted with senior representatives of renowned organizations that are engaged in the research related to liposomes.
  • Chapter 14: is an appendix, that contains tabulated data and numbers for all the figures provided in the report.
  • Chapter 15: is an appendix, that contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to Liposomes
  • 3.3. Formation of Liposomes
  • 3.4. Classification of Liposomes
  • 3.5. Liposome as a Drug Delivery System
    • 3.5.1. Liposomal Drug Delivery Platforms
    • 3.5.2. Therapeutic Applications of Liposomes in Drug Delivery
  • 3.6. Methods for Liposome Preparation
  • 3.7. Post-Preparation Treatments
    • 3.7.1. Freeze-Thawing
    • 3.7.2. Freeze-Drying
  • 3.8. Liposome Analysis and Characterization
  • 3.9. Pharmaceutical and Industrial Applications of Liposomes
    • 3.9.1. Drug Delivery
    • 3.9.2. Gene Delivery
    • 3.9.3. Vaccine Delivery
    • 3.9.4. Cancer Therapy
    • 3.9.5. Agricultural Industry
    • 3.9.6. Cosmetics
    • 3.9.7. Food Industry
  • 3.10. Challenges in Liposome Development and Manufacturing
  • 3.11. Need for Outsourcing of Liposome Development and Manufacturing
  • 3.12. Future Perspectives

4. MARKET LANDSCAPE: LIPOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS

  • 4.1. Chapter Overview
  • 4.2. Liposome Development and Manufacturing Service Providers Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Region of Headquarters
    • 4.2.4. Analysis by Company Size and Region of Headquarters
    • 4.2.5. Analysis by Type of Method(s) Used for Liposome Preparation
    • 4.2.6. Analysis by Type of Service(s) Offered
    • 4.2.7. Analysis by Liposome Bioconjugation Target(s)
    • 4.2.8. Analysis by Scalability
    • 4.2.9. Analysis by Liposome Analysis and Characterization Method(s)
    • 4.2.10. Analysis by Application(s) of Liposomes
    • 4.2.11. Analysis by Type of Service(s) Offered, Application(s) and Product Formulation
    • 4.2.12. Analysis by Scale of Operation
    • 4.2.13. Analysis by End User Industry
    • 4.2.14. Analysis by Scale of Operation and End User Industry

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. Key Players Based in North America
    • 5.2.1. Baxter BioPharma Solutions
      • 5.2.1.1. Company Overview
      • 5.2.1.2. Financial Information
      • 5.2.1.3. Service Portfolio
      • 5.2.1.4. Recent Developments and Future Outlook
    • 5.2.2. Charles River Laboratories
      • 5.2.2.1. Company Overview
      • 5.2.2.2. Financial Information
      • 5.2.2.3. Service Portfolio
      • 5.2.2.4. Recent Developments and Future Outlook
  • 5.3. Key Players Based in Europe
    • 5.3.1. Evonik
      • 5.3.1.1. Company Overview
      • 5.3.1.2. Financial Information
      • 5.3.1.3. Service Portfolio
      • 5.3.1.4. Recent Developments and Future Outlook
    • 5.3.2. Fresenius Kabi
      • 5.3.2.1. Company Overview
      • 5.3.2.2. Financial Information
      • 5.3.2.3. Service Portfolio
      • 5.3.2.4. Recent Developments and Future Outlook
    • 5.3.3. GEA
      • 5.3.3.1. Company Overview
      • 5.3.3.2. Financial Information
      • 5.3.3.3. Service Portfolio
      • 5.3.3.4. Recent Developments and Future Outlook
    • 5.3.4. Intertek
      • 5.3.4.1. Company Overview
      • 5.3.4.2. Financial Information
      • 5.3.4.3. Service Portfolio
      • 5.3.4.4. Recent Developments and Future Outlook
  • 5.4. Key Players Based in Asia-Pacific
    • 5.4.1. Fujifilm
      • 5.4.1.1. Company Overview
      • 5.4.1.2. Financial Information
      • 5.4.1.3. Service Portfolio
      • 5.4.1.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Scope and Methodology
  • 6.3. Liposomes: Clinical Trial Analysis
    • 6.3.1. Analysis by Trial Registration Year
    • 6.3.2. Analysis by Trial Status
    • 6.3.3. Analysis by Trial Registration Year and Trial Status
    • 6.3.4. Analysis by Trial Registration Year and Patients Enrolled
    • 6.3.5. Analysis by Trial Phase
    • 6.3.6. Analysis by Trial Phase and Patients Enrolled
    • 6.3.7. Analysis by Type of Sponsor / Collaborator
    • 6.3.8. Analysis by Study Design
    • 6.3.9. Most Active Industry Players: Analysis by Number of Trials
    • 6.3.10. Most Active Non-Industry Players: Analysis by Number of Trials
    • 6.3.11. Analysis by Disease Indication(s)
    • 6.3.12. Most Popular Therapeutic Areas: Analysis by Number of Trials
    • 6.3.13. Analysis by Type of Treatment
    • 6.3.14. Word Cloud Analysis: Emerging Focus Areas
    • 6.3.15. Analysis by Top Indications and Trial Phase
    • 6.3.16. Analysis by Top Indications and Leading Industry Players
    • 6.3.17. Geographical Analysis by Number of Clinical Trials
    • 6.3.18. Geographical Analysis by Number of Patients Enrolled

7. PUBLICATION ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Liposomes: Recent Publications
    • 7.3.1. Analysis by Year of Publication
    • 7.3.2. Analysis by Application Area(s)
    • 7.3.3. Word Cloud Analysis: Emerging Focus Areas
    • 7.3.4. Key Journals: Analysis by Number of Publications
    • 7.3.5. Key Journals: Analysis by Impact Factor
    • 7.3.6. Key Journals: Analysis by Year-wise Number of Publications

8. PATENT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Liposomes: Patent Analysis
    • 8.3.1. Analysis by Patent Publication Year
    • 8.3.2. Analysis by Granted Patents and Patent Applications
    • 8.3.3. Analysis by Geography
    • 8.3.4. Analysis by CPC Symbols
    • 8.3.5. Word Cloud Analysis: Emerging Focus Areas
    • 8.3.6. Analysis by Type of Organization
    • 8.3.7. Leading Industry Players: Analysis by Number of Patents
    • 8.3.8. Leading Non-Industry Players: Analysis by Number of Patents
    • 8.3.9. Leading Individual Assignees: Analysis by Number of Patents
  • 8.4. Liposomes: Patent Benchmarking Analysis
    • 8.4.1. Analysis by Patent Characteristics
  • 8.5. Liposomes: Patent Valuation Analysis
  • 8.6. Leading Patents: Analysis by Number of Citations

9. GLOBAL EVENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Liposome Development and Manufacturing: Global Events Analysis
    • 9.3.1. Analysis by Year of Event
    • 9.3.2. Analysis by Event Platform
    • 9.3.3. Analysis by Type of Event
    • 9.3.4. Analysis by Year of Event and Type of Event
    • 9.3.5. Analysis by Geography
    • 9.3.6. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
    • 9.3.7. Most Active Event Organizers
  • 9.4. Liposome Development and Manufacturing: Speaker Analysis
    • 9.4.1. Most Active Industry Players: Analysis by Number of Events
    • 9.4.2. Most Active Non-Industry Players: Analysis by Number of Events
    • 9.4.3. Analysis by Seniority Level of Event Speakers
    • 9.4.4. Analysis by Affiliated Department of Event Speakers
    • 9.4.5. Most Active Speakers: Analysis by Number of Events
  • 9.5. Geographical Mapping of Upcoming Events
  • 9.6. Concluding Remarks

10. OUTSOURCING: GO / NO-GO FRAMEWORK

  • 10.1. Chapter Overview
  • 10.2. Outsourcing: Go / No-Go Framework
  • 10.3. Liposome-based Therapeutic Developers Outsourcing: Go / No-Go Framework
    • 10.3.1. Key Parameters and Assumptions
    • 10.3.2. Methodology
    • 10.3.3. Results and Interpretations
      • 10.3.3.1. Very Small Companies
      • 10.3.3.2. Small Companies
      • 10.3.3.3. Mid-Sized Companies
      • 10.3.3.4. Large Companies
      • 10.3.3.5. Very Large Companies

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Key Assumptions and Methodology
  • 11.3. Global Liposome Development and Manufacturing Services Market, 2022-2035
    • 11.3.1. Liposome Development and Manufacturing Services Market: Distribution by Type of Product Formulation, 2022 and 2035
      • 11.3.1.1. Liposome Development and Manufacturing Services Market for Therapeutics, 2022-2035
      • 11.3.1.2. Liposome Development and Manufacturing Services Market for Nutraceuticals, 2022-2035
    • 11.3.2. Liposome Development and Manufacturing Services Market: Distribution by Scale of Operation, 2022 and 2035
      • 11.3.2.1. Liposome Development and Manufacturing Services Market for Discovery / Research Scale of Operation, 2022-2035
      • 11.3.2.2. Liposome Development and Manufacturing Services Market for Preclinical Scale of Operation, 2022-2035
      • 11.3.2.3. Liposome Development and Manufacturing Services Market for Clinical Scale of Operation, 2022-2035
      • 11.3.2.4. Liposome Development and Manufacturing Services Market for Commercial Scale of Operation, 2022-2035
    • 11.3.3. Liposome Development and Manufacturing Services Market: Distribution by End User Industry, 2022 and 2035
      • 11.3.3.1. Liposome Development and Manufacturing Services Market for Pharmaceutical and Biotechnology Industry, 2022-2035
      • 11.3.3.2. Liposome Development and Manufacturing Services Market for Cosmetics, 2022-2035
      • 11.3.3.3. Liposome Development and Manufacturing Services Market for Food Industry, 2022 2035
      • 11.3.3.4. Liposome Development and Manufacturing Services Market for Agricultural Industry, 2022 2035
      • 11.3.3.5. Liposome Development and Manufacturing Services Market for Academics, 2022 2035
      • 11.3.3.6. Liposome Development and Manufacturing Services Market for Other Industries, 2022 2035
    • 11.3.4. Liposome Development and Manufacturing Services Market: Distribution by Key Geographical Regions, 2022 and 2035
      • 11.3.4.1. Liposome Development and Manufacturing Services Market in North America, 2022-2035
      • 11.3.4.2. Liposome Development and Manufacturing Services Market in Europe, 2022-2035
      • 11.3.4.3. Liposome Development and Manufacturing Services Market in Asia-Pacific, 2022-2035
      • 11.3.4.4. Liposome Development and Manufacturing Services Market in Middle East and North Africa, 2022-2035
      • 11.3.4.5. Liposome Development and Manufacturing Services Market in Latin America, 2022-2035

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제